On May 14, 2019, the sixth patient was treated with Talidox at the Inselspital Bern. The dose of 40mg/m2 now reached already corresponds to the maximum dose originally planned in the study. The latter was defined on the basis of the dose of Caelyx used in daily clinical practice, as dose-limiting side effects were expected to occur earlier. 

In view of the good results, further dose increases are now planned to fully characterize the tolerability profile of Talidox. In light of this, the study protocol is now being revised accordingly and will be submitted to Swissmedic in the next few days. This positive development of the Phase I study strengthens InnoMedica’s commitment to further prioritizing the project and expanding its own production facility in Marly in order to ensure the supply of Talidox to the clinics upon good results and with a view to approval.